Neuro-Immunity and Gut Dysbiosis Drive Parkinson’s Disease-Induced Pain

Katiane Roversi1,2,3,4, Natalia Callai-Silva1,2,3, Karine Roversi1, May Griffith2,3, Christos Boutopoulos2,3, Rui Daniel Prediger4* and Sébastien Talbot1*

1 Département de Pharmacologie et Physiologie, Université de Montréal, Montréal, QC, Canada, 2 Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 3 Département d’Ophtalmologie, Université de Montréal, Montréal, QC, Canada, 4 Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianópolis, Brazil

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1–2% of the population aged 65 and over. Additionally, non-motor symptoms such as pain and gastrointestinal dysregulation are also common in PD. These impairments might stem from a dysregulation within the gut-brain axis that alters immunity and the inflammatory state and subsequently drives neurodegeneration. There is increasing evidence linking gut dysbiosis to the severity of PD’s somatic symptoms as well as to somatosensory hypersensitivities. Altogether, these interdependent features highlight the urgency of reviewing the links between the onset of PD’s non-motor symptoms and gut immunity and whether such interplays drive the progression of PD. This review will shed light on maladaptive neuro-immune crosstalk in the context of gut dysbiosis and will posit that such deleterious interplays lead to PD-induced pain hypersensitivity.

Keywords: Parkinson’s disease, pain, nociceptor neurons, neuro-immunity, microbiota, dysbiosis, gut-brain axis

PAIN

Pain is defined as an unpleasant sensory and emotional experience associated with real or potential injury (1). Physiologically, pain serves as a protective mechanism, alerting the host to environmental danger. The sensation results from the integration of complex neurobiological systems that detect, integrate, and coordinate protective responses to noxious stimuli that threaten the host’s homeostasis and survival (2).

Nociceptors express various ion-channel receptors that are specialized to respond to threats posed by pathogens, allergens, and pollutants. Nociception is then initiated upon sensing these noxious stimuli by first-order neurons which, once activated by their cognate ligands, allow the influx of cations (Na+, Ca2+) leading to the generation of an action potential. These electrical signals are then propagated through the length of small, unmyelinated C or myelinated Aδ fibers to the spinal cord, where they synapse with second-order neurons (3). These electrical signals are then modulated—either amplified or blunted—by local immune cells or descending neurons.

The descending pathways originate from supraspinal structures such as the rostral ventromedial medulla (RVM), the dorsolateral pontomesencephalic tegmentum, and the periaqueductal gray matter (PAG). The descending pathways inhibit pain by releasing monoamines, such as dopamine,
norepinephrine, and serotonin into the dorsal horn. Additionally, endogenous opioids exert descending inhibition of nociception (4).

Once modulated in the spinal cord, the nociceptive signal is processed in the supraspinal region and recognized as pain. The lateral pain system comprises the spinothalamic tract, which projects through the lateral thalamus and toward the sensory cortical areas, and is primarily involved in processing sensory discrimination, localization, and pain intensity. In contrast, the medial pain system processes the motivational-affective and cognitive-evaluative aspects of pain (e.g., unpleasantness, suffering) and projects through the medial thalamic nuclei toward the anterior cingulate cortex (5).

**CHRONIC PAIN**

Chronic pain affects approximately 20% of the general population and individual of any age. It negatively impacts the patient’s quality of life and is also associated with mood and sleep disorders. It is considered the chief debilitating symptom of a variety of diseases, ranging from cancer to multiple sclerosis (6–8). While acute pain serves a physiological purpose, chronic pain is rarely self-resolving and remains resistant to pharmacological treatment (9). This pain can be either perceived more severely, a phenomenon known as hyperalgesia, or it can be generated by non-noxious stimuli, a condition known as allodynia.

Chronic pain results from persistent and repeated stimuli which can lead to peripheral and/or central sensitization of nociceptor neurons. Specifically, central sensitization is characterized by the persistent hyperexcitability of the central nervous system (CNS) circuitry triggered by excessive neuronal activity resulting from peripheral tissue inflammation or neuropathic injury. Central sensitization can result from i) modifications of glutamatergic receptors; ii) the upregulation of proteins involved in maintaining synaptic strength; iii) Aβ neuron sprouting; iv) decreased inhibitory control by GABAergic interneurons; and v) increased expression of activator ion-channel or neuropeptide receptors (10).

Secondary to the actions of pro-inflammatory cytokines released by microglia and astrocytes, these modifications increase the synaptic activity between first- and second-order neurons by altering the biophysical properties of danger-detecting ion-channel receptors and promoting the trafficking of these receptors to the synaptic membrane. Functionally, the sensitization is reflected by a long-term potentiation of the synaptic transmission between primary and second-order sensory neurons, rendering the CNS hypersensitive to normal (or previously innocuous) inputs. Clinically, this higher level of excitability maintains chronic pain (10–12).

**IMMUNITY DRIVES PAIN**

Along with detecting adverse temperature, pressure, and chemicals, nociceptor neurons express specific receptors for numerous immunoglobulins, cytokines, and chemokines. The nociceptor neurons are tuned to detect and respond to mediators derived from immunocytes (13–16). Typically, the binding of these sensitizing molecules generates intracellular signaling via tyrosine kinase or G-protein-coupled receptors (15, 17, 18). The second messengers downstream of these receptors trigger i) the phosphorylation and membrane expression of ion-channel receptors and voltage-gated sodium channels; and ii) the overproduction of neuropeptides and neurotransmitters (19–21).

A few well-known examples of immunocyte-releasing pain-sensitizing mediators include the action of interleukin 1 beta (IL-1β) (22–24), tumor necrosis factor (TNF-α) (25, 26), prostaglandin E2 (PGE2) (27), and nerve growth factor (NGF) (24). For example, PGE2 stimulates nociceptor-expressed DP2, which leads to an increase in protein kinase A (PKA) and protein kinase C (PKC) activity, which, in turn, phosphorylates transient receptor potential vanilloid 1 (TRPV1). Consequently, PGE2 increases capsaicin-induced currents, as found in cultured rat dorsal root ganglion (DRG) neurons (28, 29). In the case of NGF, when binding to its cognate receptor TrkA, it triggers PI3K/Src kinase activation which also leads to the phosphorylation of TRPV1 (18, 30).

These mechanisms stem from work done on models of rodents with nerve injury or auto-immune diseases. While no particular neuro-immune cascade appears to be the primary driver of the pain sensation, data show the involvement of central and peripheral innate (i.e. macrophages) and adaptive (i.e. T cells) immune cells. While typically studied in isolation, peripheral and central mechanisms should be studied concurrently. This is exemplified by the data showing that monocytes and microglia synergize in driving neuropathic pain in mice with nerve injuries. Thus, both types of cells need to be eliminated to alleviate pain. However, when used separately, monocyte depletion using clodronate liposomes or CX3CR1⁺ microglia ablation failed to impact the course of the disease (31).

In a model of chronic constriction injury (CCI), T cells are recruited to the sciatic nerve and induce mechanical allodynia via the production of IL-17A and IFN-γ (32). Athymic nude male rats, which have no T cells, were protected. Upon nerve injury, T cells infiltrate the DRG and release leukocyte elastase (LE) which promotes mechanical allodynia via the production of IL-17A and IFN-γ (33, 34). While spinal nerve transection-induced neuropathic pain was found to be mediated by T111 cells released IFN-γ, TNF-α, and GM-CSF (36). Interestingly, when comparing the spinal dorsal horn gene profile of spared nerve injury (SNI) animals, T cells and glia seem predominately impacted in adult mice rather than younger animals. These data may indicate age-dependent neuromodulation by immune cells, which could explain why hypersensitivity seems to increase with age.

Neuro-immune crosstalks are not limited to the site of injury, as shown in models of chemotherapy and sciatic nerve ligation. Immunocytes (i.e., macrophages, monocytes, neutrophils, and T cells) infiltrate the DRG in a TLR2- or CCL-2-mediated fashion (37, 38). Once in the tissue, they release IL-1β and TNF-α, which can cause thermal hyperalgesia (39–44). In contrast, the targeted
depletion of IL-10-producing monocytes and macrophages delayed pain resolution (45).

Aside from these traditional mechanisms, antibodies produced in auto-immune diseases can initiate pain. For instance, the injection of autoantibodies against citrullinated proteins (ACPAs) purified from animals with rheumatoid arthritis promotes pain-like behavior without inflammation. This is achieved by acting on osteoclasts and inducing CXCL1, a human analog of IL-8 (46). In addition, IgG from patients with complex regional pain syndrome (CRPS) prolonged postsurgical hypersensitivity to mechanical, cold, and heat stimuli. Finally, skin-saphenous nerve preparations from tCRPS mice show increase sensitivity to auto-antibodies (47), which impairs the function of the potassium channel Kv1.2 and promotes mechanical hypersensitivity (48).

Another novel mechanism of pain modulation was described by Chen et al., who found that by binding to peripheral sensory neuron-expressed PD-1, the immune checkpoint ligand PD-L1 triggers the phosphorylation of SHP-1 and the downstream modulation of sodium and potassium channels. Consequently, PD-L1 suppressed excitatory synaptic transmission (sEPSC) in lamina II neurons of the spinal cord which trigger analgesia (49).

Beyond the commonly known Pattern recognition receptor (PRR) typically expressed by immune cells, Stimulator of interferon genes protein (STING1) was recently found to be abundant in TRPV1+ neurons (50, 51). Its activation by IFN-I ligands led to long-lasting analgesia by suppressing the excitability of nociceptors through the modulation of sodium and calcium channel function (51).

**MICROBES INDUCE PAIN**

The Gastrointestinal (GI) tract is innervated by intrinsic neurons from the enteric nervous system (ENS) and by the axons of extrinsic sympathetic, parasympathetic, and visceral afferent neurons (52, 53). The ENS is organized into two major neuronal networks—the myenteric plexus, and the submucosal plexus—and also comprises connective interneurons and various types of supporting glial cells. The ENS sympathetic (noradrenergic) neurons control blood vessel vasconstriction, while the parasympathetic (cholinergic) neurons control gut contraction (54).

The gut’s extrinsic innervation is made up of neurons originating from lumbar (DRG) and nodose (ND) ganglia. These neurons work to monitor GI volume and intestinal contents, while the gut hormones regulate the digestive physiology (55). The DRG neurons project along the mesenteric arteries, while the ND ganglion neurons project from the vagus nerve.

The vagus, which consists of ~2,300 sensory neurons, projects to half of the large intestine. The GI tract innervation accounts for ~20% of its terminals (56). Most of these extrinsic fibers (DRG and ND) express sensory neuron markers such as TRP channels (TRPV1) (57), voltage-gated sodium channels (NaV1.8) (58), and mechanosensitive channels (Piezo2) (59).

These sensory neurons are designed to limit tissue damage by detecting and initiating protective reflexes (60, 61).

Under homeostatic conditions, the lumen of the intestine is not directly innervated, meaning that there is no direct neuron sensing of the luminal content (50, 62). The signals are sent by intestinal enteroendocrine cells which expressed glutamate receptors and can release a few neuropeptides (i.e., cholecystokinin, peptide YY (PYY)), consequently enabling the perception of the luminal content by vagal neurons (63). Upon penetrating the epithelial barrier, as in the case of a lesion or an infection, the proteases, reactive oxygen species, or cytokines produced by mucosa-resident immune cells may stimulate the ENS neurons (64, 65).

Different making in gut pathogens, as found in dysbiosis, is associated with headaches, chemotherapy-induced neuropathic pain, and abdominal pain. *Staphylococcus aureus* heightens sensory hypersensitivity via membrane-bound N-formylated peptides or by releasing various pore-forming toxins (i.e., alpha-hemolysin, phenol-soluble modulins, leukocidin). Conversely, gut nociceptor-released Calcitonin gene-related peptide (CGRP) regulates M cell density, limiting pathogen entry into the GI tract (66). TRPV1+ neurons also appear to be associated with mucosal resistance against *Candida albicans*. They do so by increasing CD301b+ dDCs release of IL-23 and subsequent production of IL-17A from γδ T cells (67). Finally, the recognition of soluble bacterial products by ENS axonal termini, as found in the microfluidic gut model, drive RORα+ T_reg induction and immunosuppression (68).

**PD-INDUCED PAIN**

Pain is a non-motor symptom present in 60–85% of PD patients (6, 69, 70). PD-induced pain negatively impacts a patient’s quality of life (8) and may exacerbate other non-motor PD symptoms such as depression and sleep disorders (7). In approximately one-third of PD sufferers, pain precedes the onset of PD motor symptoms by several years (71, 72). Peripheral neuropathic pain is also twice as frequent in PD patients (73, 74). Conversely, patients experiencing chronic pain are at increased risk of developing PD (75).

Pain often manifests as a musculoskeletal hypersensitivity affecting the neck, arms, or paravertebral muscles. It is believed to be a consequence of PD motor symptoms. PD can also trigger visceral pain, which affects the internal organs and results from the activation of nociceptors localized in the thoracic and pelvic organs. Visceral pain is associated with gastrointestinal dysfunction, as seen in PD patients (76). Finally, neuropathic pain is observed in 4%–10% of PD patients (77–79) and is typically associated with lesions in the central or peripheral nervous system (80). Clinically, it presents as burning, cramping, aching, numbness, tingling, vibrating, or lancinating sensations. This type of pain may be associated with autonomic manifestations, and it often stems from the face, head, pharynx, epigastrium, abdomen, pelvis, rectum, and genitalia. This type of pain does not correlate with the severity of motor impairments and often precedes their onset (79, 81–84).
Despite its clinical relevance and predictive value, pain is often neglected or misdiagnosed in PD patients and remains poorly managed (85). The contribution of maladaptive peripheral (Peripheral Mechanisms of PD-Induced Pain) and central (Central Mechanisms of PD-Induced Pain) neuro-immune interplays as well as gut-brain axis dysregulation (sections GI Dysfunction in PD-Induced Pain and Dysbiosis in PD-Induced Pain) (86) to the induction of PD-induced pain will now be discussed.

**IMMUNITY IN PD**

Based on the overall role that neuro-immunity plays in sustaining sensory hypersensitivity (Immunity Drives Pain), we posit that neuronal loss or damage leads to the local recruitment of immune cells. It is well established that in patients with PD progression (87), involves innate and adaptive immune cells, of immune cells. It is well established that in patients with PD progression (87), involves innate and adaptive immune cells, and can occur in the peripheral or CNS. An indication that the immune system is responding to tissue damage stems from increased TNF-α, IL-1β, IL-2, IL-6, IFN-γ, and CCL2 levels observed in the blood and cerebrospinal fluid (CSF) of PD patients (88–91). These increases correlate with disease progression. For example, higher serum levels of TNF-α were linked to motor dysfunction, while raised levels of IL-1β and IL-2 were associated with cognitive decline (92).

This increase in circulating cytokines was secondary to a rise in the number of immunocytes in a patient’s bloodstream. As expected, the severity of the disease correlates with lower levels of naïve CD4+ T cells (93–95) but increased levels of blood-circulating T<sub>reg</sub> activated CD4+ T cells, IL-17-producing T<sub>H</sub>17 cells, and IL-6-producing monocytes (Figure 1) (96–101). While this may sound counterintuitive, a study reported a decreased capability of PD-isolated T<sub>reg</sub> to suppress the activity of effector T cells in vitro (96, 97). In fact, the levels of blood cytokines found in PD patients correlate with an increase in sensory hypersensitivity. Thus, CD4+ T cells in patients experiencing pain have a lower IL-6/IL-10 ratio, while CD8+ T cells display a higher TNF-α/IL-10 ratio (102).

**PERIPHERAL MECHANISMS OF PD-INDUCED PAIN**

Compared with ~5% of the general population, 20%–60% of PD patients show large- and small-fiber PN (73, 103). Interestingly, the severity of large-fiber neuropathy is also a marker of PD severity (104). Skin biopsies of PD patients with sensory hypersensitivity revealed that α-synuclein aggregates in cutaneous sensory nerves and leads to their degeneration (105–109). In a study of 72 PD patients, damage found in α-synuclein fibers correlated with the level of sensory hypersensitivity they experienced. As a functional indication for abnormal pain fiber inputs, hypersensitive PD patients have a lower pain threshold to electrical stimuli as well as a higher current perception threshold than their normosensitive counterparts (110).

By contrast, Nolano et al. found that PD patients (n=18 subjects) were generally hyposensitive. They explained these findings as the loss of epidermal nerve fibers and Meissner corpuscles, which translated into an increase in tactile and thermal thresholds (105). A more recent study by the same authors analyzed skin innervation in 85 PD patients and found a significant reduction in intraepidermal nerve fiber density. This phenotype was correlated with a decrease in the perception of mechanical pain (107). However, further clinical studies are needed to clarify any putative correlation between PD pain thresholds, peripheral nerve degeneration, levels of dermal α-syn, and immunocyte infiltration.

Circulating α-syn-reactive CD4+ T cells are expanded in PD patients’ blood (Figure 1) (111). When injected into the

---

**Figure 1** | Peripheral inflammation in Parkinson’s disease. Indicators that the immune system is responding to tissue damage stems from increased blood-circulating T<sub>reg</sub> activated CD4+ T cells, IL-17-producing T<sub>H</sub>17 cells and IL-6-producing monocytes in PD patients’ blood. In addition, circulating α-syn-reactive CD4 T cells are expanded in PD patients’ blood and blood purified CD4+ and CD8+ T cells from PD patients recognize and respond to α-syn which increase the production of IL-8 or IFN-γ, interferon γ, IL-5, interleukin 5, IL-6, interleukin 6; IL-17, interleukin 17; T<sub>H</sub>17, T helper 17 cells; TCR, T cell receptor; TNF-α, tumor necrosis factor; T<sub>reg</sub>, regulatory T cells; α-syn, α-synuclein.
gastrocnemius muscle of PD mice (M83 model), α-Syn preformed fibrils (PFF) aggregate in the dorsal nerve roots and lumbar DRG sensory neurons, as well as the lumbar spinal cord, the midbrain PAG matter, and the thalamus. When α-Syn aggregates in sensory neurons, it decreases nerve conduction velocity, drives small- and medium-sized myelinated fiber pathology, and induces mechanical allodynia (112). Importantly, these alterations were observed in the absence of motor dysfunction.

Injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; i.p. 11 mg/kg, daily for five days), a pro-neurotoxin used to model PD, led to an increase in sensory neuron expression of NaV1.1, NaV1.7, NaV1.9. These alterations occurred 12 days after the first MPTP challenge and were accompanied by thermal hypersensitivity (confirmed by the hot plate and tail-flick tests) and extensive loss of striatal dopamine (113). In reserpine-injected rats presenting with mechanical hyperalgesia, neuron-profiling data showed increased expression of the acid-sensing ion channel ASIC3. Its specific blockade reversed reserpine-induced pain. This effect was accompanied by sustained spinal dorsal horn microglial activation, whose inhibition with minocycline reversed mechanical hyperalgesia (114).

Using a PD animal model, these studies demonstrate the presence of functional and transcription alterations in the somatosensory nervous system. They also provide a mechanistic link between the expression of prototypical pain-associated ion channels receptors and the onset of PD non-motor symptoms. Further research is necessary to test whether targeting these changes would, along with stopping PD-induced pain, alleviate CNS alteration by delaying or preventing the onset of PD motor symptoms.

**CENTRAL MECHANISMS OF PD-INDUCED PAIN**

In PD patients suffering from chronic pain, positron emission tomography (PET) studies showed increased neuronal activity in the prefrontal cortex, the primary somatosensory cortex, the posterior insula, and the anterior cingulate cortex (84, 115). At resting-state, magnetic resonance imaging (MRI) analysis of the connectivity between the right nucleus accumbens and the left hippocampus showed that it was reduced in PD patients experiencing pain compared with pain-free PD patients (116, 117). Before there is any noticeable degeneration in the substantia nigra and the onset of motor symptoms, early signs of PD neuropathology are noticeable degeneration in the substantia nigra and the onset of motor symptoms, precoce mice exposed to bacterial intestinal infection (121). Another example of T cell-mediated neurodegeneration stems from IL-17-derived from CD3+ T cells, which, when co-cultured, eliminate PD patients’ iPSC-derived midbrain dopaminergic neurons (98).

**GI DYSFUNCTION IN PD-INDUCED PAIN**

Gastrointestinal (GI) alterations are found in up to 80% of PD patients (123–125), with symptoms ranging from constipation to nausea, dyspepsia, and dysphagia (126). Constipation might precede the onset of PD motor symptoms by several decades (127, 128) and has been considered a prodromal hallmark of PD (126). In PD patients, severe GI symptoms are predictive of impaired cognitive performance.

α-syn, which is typically found in CNS of PD patients, is also present in the colon, the neurons of the ENS, and the vagus nerve (129, 130). These findings were phenocopy in animal models of PD, in which aggregates of α-syn were found in the GI tract (Figure 3A) (131–134). As such, a growing number of investigators argue that PD might start in the gut and spread to the CNS through the vagus nerve (Figure 3A). This hypothesis is supported by animal studies showing that exogenous α-syn injected into the gut wall migrated to the brain via the vagus nerve at a rate estimated to be 5–10 mm/day in rats (135), while a patient who underwent a truncal vagotomy showed a decreased risk of developing PD later in life (136, 137). Although the cause of these disruptions and their role in PD pathogenesis remains unclear, the presence of α-syn in the ENS is sufficient to induce colonic dysmotility in the GI tract, which correlates with the severity of motor impairment in some animal models (138, 139).

PD patients experiencing constipation showed increased infiltration of CD4+ T cells into the colonic mucosa as well as elevated circulating T_{H}17 and T_{reg} cells (140). In addition, PINK1 or Parkin deficient mice exposed to bacterial intestinal infection showed an increase in BBB permeability, which facilitates the influx of cytotoxic CD8 T cells into the CNS. These pro-inflammatory cytotoxic CD8 T cells target the host’s mitochondrial antigens. Such auto-immune reactions can lead to the elimination of dopaminergic neurons in the striatum and subsequent motor impairments (141). Finally, histologic data showed increases in the immunoreactivity of the astrocytic marker GFAP in the colon of PD patients as well as increases in TNF-α, IFN-γ, IL-6, and IL-1β levels (142) (Figure 3A). These
mediators were elevated in the early stages of the disease and were negatively correlated with disease duration (142). Given that enteric and central glial cells respond to IL-6, and IL-1β, and that their upregulation is associated with inflammatory pain (143), it is conceivable that the influx of cytotoxic CD8 T cells heightens pain transmission centrally or within the gut wall.

DYSBIOSIS IN PD-INDUCED PAIN

In conjunction with gastrointestinal dysfunction and inflammation, gut dysbiosis may contribute to PD progression by increasing the permeability of the blood-gut barrier and BBB and facilitating the transport of peripheral α-syn to the brain (138). Similarly, microbes can directly activate sensory neurons to trigger pain hypersensitivity (see Immunity in PD). As such, PD-induced dysbiotic bacteria and their metabolites may activate vagal or ENS neurons directly, or indirectly via activated immunocyte-released cytokines (Figure 3B) (21, 144).

Such dysbiosis is characterized by increased levels of Enterobacteriaceae, Akkermansia spp., Catabacter spp., and Akkermansiaceae and a decreased level of Roseburia spp., Faecalibacterium spp., and Lachnospiraceae (145, 146). While the function of these bacteria is diverse and is likely to be context-dependent, some patterns are evident. Roseburia spp. and Faecalibacterium spp. are typically known for their anti-inflammatory properties. Faecalibacterium spp. would blunt CD4 differentiation to TH17 cells and promote differentiation to Treg (147–149). Roseburia spp. and Faecalibacterium spp. would also downregulate IL-17 expression (150), and promote the release of the anti-inflammatory cytokines IL-10 and TGF-β (Figure 3A) (151, 152).

Roseburia spp. was found in increased levels in the blood and stool samples of fibromyalgia patients (153) and in stool samples of obese patients with back pain (154). When supplemented, Roseburia spp. alleviates stress-related visceral pain (155). It is therefore conceivable that reduced levels of Roseburia spp. and Faecalibacterium spp. exacerbates TH17 activity and/or limits the Treg which promotes PD-induced pain.

In the stools of PD patients, Enterobacteriaceae levels correlate with motor symptoms (146) and are associated with increased lipopolysaccharide (LPS) levels and α-syn fibril formation (Figure 3A) (156). While no direct link exists between Enterobacteriaceae and PD-induced pain, LPS is known to activate nociceptor neurons expressed by TLR2, -4 and -7 (157) and, possibly, TRPA1, TRPM3, TRPM8, and TRPV1 (158, 159). Enterobacteriaceae-mediated increases in LPS levels may therefore lead to the sensitization of gut-innervating nociceptor neurons (Figure 3B).
FIGURE 3 | Gut dysbiosis drives PD-induced pain. (A) The gut dysbiosis in PD is characterized by enhances Enterobacteriaceae content. These bacteria increase LPS levels which subsequently promote gut permeability. Raises in Enterobacteriaceae metabolites, such as short-chain fatty acids, promote α-syn fibril formation, microglia activation and blunt Treg-mediated immunosuppression. Proteolyzed α-syn by neurons and antigen presenting cells is then presented by the MHC machinery and leads to activation of autoreactive CD8 and CD4 T cells. (B) The dysbiotic bacteria and their metabolites directly activate vagal or ENS neurons. For instance, LPS activates nociceptor neurons-expressed TLR2/4/7 while SCFAs sensitize GPR41-expressing neurons. Bacteria-activated or α-syn-autoreactive immunocytes released cytokines can also activate their cognate receptors on sensory neurons. Subsequently, intracellular mechanisms are triggered in these neurons and culminate in TRP channels phosphorylation, neurons sensitization and sensory hypersensitivity.

CNS, central nervous system; GPR41, G protein-coupled receptor 41; IFN-γ, interferon γ; IL-1β, interleukin 1 beta; IL-2, interleukin 2; IL-6, interleukin 6; IL-10, interleukin 10; IL-12, interleukin 12; IL-17, interleukin 17; LPS, lipopolysaccharide; TGFβ, transforming growth factor beta; TLR2/4/7, Toll-like receptor 2/4/7; Treg, regulatory T cells TRPA1, transient receptor potential ankyrin-like 1; TRPV1, transient receptor potential cation channel subfamily V; TNF-α, tumor necrosis factor; SCFAs, short-chain fatty acids; α-syn, α-synuclein.
Bacteria produce various short-chain fatty acid (SCFA) metabolites including acetate, propionate, butyrate, and valeric acid. In the gut of SPF mice that underwent a CCI, these SCFAs drive hippocampal microglia polarization and IL-1β and TNF-α release. These cytokines, in turn, mediate mechanical and thermal hyperalgesia (160). When administered to germ-free α-syn overexpressing mice, SCFAs increased α-syn aggregation and microglia activation and contributed to motor dysfunction (161). SCFAs were also shown to modulate microglia activation during viral infections (162) (Figure 3A). Therefore, SCFA-mediated microglial activation may drive the central sensitization of pain pathways.

SCFAs blunt Treg-mediated immunosuppression and increase T cell density (163–165) (Figure 3A). By activating GPR43 and GPR41, SCFA inhibits the leukocytes’ histone deacetylase (HDAC) which, in turn, increase the leukocyte chemotaxis, chemokine production, and the expression of adhesion molecules (166). Given that sodium butyrate, an HDAC inhibitor diminishes CCI-induced TNF-α release and pain (167), it can be surmised that PD-induced gut SCFAs can raise circulating cytokine levels (i.e., TNF-α) and promote sensory hypersensitivities by increasing the immunomodulatory action of HDAC in leukocytes. Finally, SCFAs were found to sensitize GPR41-expressing lumbar and vagal neurons (Figure 3B) (168).

Fecal microbiota transplantation (FMT) was found to rescue gut dysbiosis, decrease SCFAs levels, alleviate physical impairment, and increase striatal DA and 5-HT content in PD animal models. Microglia and astrocyte activation was diminished in the substantia nigra, and neuroinflammation was suppressed by reducing TLR4/TNF-α signaling (169). In PD patients, FMT reduced constipation and, albeit transiently, leg tremors (170, 171). A preliminary study with 15 PD patients reported that colonic FMT administration alleviates motor and non-motor symptoms, while improving anxiety, depression, and sleep quality scores (172). In another prospective study, 11 PD patients who underwent FMT had reduced constipation and improved postural instability and gait (173).

Modulating pain by rescuing a healthy microbiome has also been postulated (174). Preclinical and clinical studies indicate that probiotic consumption alleviates visceral pain (175). Based on these findings, along with the fact that PD is characterized by dysbiosis, and that bacteria and their metabolites modulate sensory neuron function, we hypothesize that FMT may improve PD-induced pain and delay the onset of motor symptoms.

CONCLUSION

Along with constipation, sensory hypersensitivity precedes the onset of motor symptoms in PD. These physiological alterations are accompanied by gut dysbiosis, altered peripheral and central immunity, and increased local (i.e., gut) and systemic cytokine content, as well as increased gut-brain barrier and BBB permeability. We posit that gut dysbiosis leads to systemic inflammation, which drives sensory hypersensitivity (Figure 4). Via local pro-inflammatory loops, these hypersensitized nociceptor neurons are likely to amplify immune responses and speed up central neurodegeneration. Alleviating constipation, rescuing microbiota via
neurons increase activity, would, in turn, modulate dysbiosis and hypersensitivity. Further studies should investigate how nociceptor neurons increase activity, would, in turn, modulate dysbiosis and central neurodegeneration. Should pain constitute an early driver of PD pathophysiology, monitoring and alleviating this symptom may constitute a novel biomarker and therapeutic target to slow the progression of PD.

**AUTHOR CONTRIBUTIONS**

KR and ST designed the study. KR, NC-S, KrR, MG, CB, RP, and ST wrote the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Ripamonti CI. Pain Management. *Ann Oncol* (2012) 23(Suppl 10):s294–301. doi: 10.1093/annonc/mds360
2. Melzack R. From the Gate to the Neuromatrix. *Pain* (1999) Suppl 6:S121–6. doi: 10.1016/s0304-3959(99)00145-1
3. Tesfaye S, Kempker P. Painful Diabetic Neuropathy. *Diabetologia* (2005) 48(5):805–7. doi: 10.1007/s00125-005-1721-7
4. Osipov MH, Porreca F. Challenges in the Development of Novel Treatment Strategies for Neuropathic Pain. *NeuroRx* (2005) 2(4):650–61. doi: 10.1602/neurors.2.4.650
5. Cameron AA, Khan IA, Westlund KN, Cliffer KD, Willis WD. The Efferent Projections of the Periaqueductal Gray in the Rat: A Phaseolus Vulgaris-Leucoagglutinin Study. I. Ascending Projections. *J Comp Neurol* (1995) 351(4):568–84. doi: 10.1002/1096-9861(19951010)a351<568::aid-cne2503510407>3.0.co;2-4
6. Politis M, Wu K, Molloy S, GB P, Chaudhuri KR, Piccini P. Parkinson’s Disease Symptoms: The Patient’s Perspective. *Mov Disorder* (2010) 25(11):1646–51. doi: 10.1002/mds.23135
7. Santos-Garcia D, Abella-Corral J, Aneiros-Diaz A, Santos-Canelles H, Llanaza-Gonzalez MA, Macias-Arribi M. Pain in Parkinson’s Disease: Prevalence, Characteristics, Associated Factors, and Relation With Other Non Motor Symptoms, Quality of Life, Autonomy, and Caregiver Burden. *Rev Neurol* (2011) 52(7):385–93. doi: 10.33388/rrn.5207.2010558
8. Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, et al. Relationship Between the MDS-UPDRS and Quality of Life: A Large Multicenter Study of 3206 Patients. *Parkinsonism Relat Disord* (2018) 52:83–9. doi: 10.1016/j.parkreldis.2018.03.027
9. Anwar K. Pathophysiology of Pain. *Dis Mon* (2016) 62(9):324–9. doi: 10.1016/j/dismonth.2016.05.015
10. Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. *J Pain* (2009) 10(9):895–926. doi: 10.1016/j.jpain.2009.06.012
11. Ii RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. *Anesthesiology* (2018) 129(2):343–66. doi: 10.1097/ALN.0000000000002130
12. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. *Cell* (2009) 139(2):267–84. doi: 10.1016/j.cell.2009.09.028
13. Cook AD, Christensen AD, Tewari D, McMahon SB, Hamilton JA. Immune Cytokines and Their Receptors in Inflammatory Pain. *Trends Immunol* (2018) 39(3):240–55. doi: 10.1016/j.it.2017.12.003
14. Austin Pj, Moalem-Taylor G. The Neuro-Immune Balance in Neuropathic Pain: Involvement of Inflammatory Immune Cells, Immune-Like Glial Cells and Cytokines. *J Neuroinmunol* (2010) 229(1-2):26–50. doi: 10.1016/j.neuroimmunol.2010.08.013
15. Ii RR, Xu ZZ, Gao YJ. Emerging Targets in Neuroinflammation-Driven Chronic Pain. *Nat Rev Drug Discov* (2014) 13(7):533–48. doi: 10.1038/nrd4334

**FUNDING**

ST is financed by Canada Research Chair program (#950-231859), Canadian Institutes of Health Research (#162211, #461274, #461275), the Canadian Foundation for Innovation (#37439), and Natural Sciences and Engineering Research Council of Canada (#RGPIN-2019-06824), as well as the Fonds de recherche du Québec – Santé and Centre interdisciplinaire de recherche sur le cerveau et l’apprentissage (CIRCA). KR holds postdoctoral fellowships from the Fonds de recherche du Québec - Nature et technologies (FQRNT; #289949), CIRCA and Fonds de recherche en ophtalmologie - Université de Montréal (FROOM). KrR holds postdoctoral fellowships from CIRCA and FROOM. NCS holds a Merit scholarship from the Faculty of Medicine of the Université de Montréal.
...
Wasner G, Deuschl G. Pains in Parkinson Disease

Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic Presentations

Brefel-Courbon C, Payroux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Peripheral Neuropathy in Idiopathic Parkinson’s Disease: A Systematic Review. *J Neurol Sci* (2017) 378:204–9. doi: 10.1016/j.jns.2017.05.023

Adevusi JK, Hadjivassiliou M, Vinagre-Aragon A, O’Connor KR, Khan A, Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson’s Disease: One Umbrella. *Nat Rev Neurol* (2015) 14(1):57–64. doi: 10.1038/nrneurol.2014.274

Skogar O, Fall PA, Hallgren G, Bringer B, Carlsson M, Lennartsson U, et al. Small Fibre Neuropathy in Idiopathic Parkinson’s Disease Patients. *J Neurol Sci* (2018) 394:103–12. doi: 10.1016/j.jns.2018.06.022

Skogar O, Fall PA, Hallgren G, Bringer B, Lennartsson U, et al. Small Fibre Neuropathy in Parkinson’s Disease: A Nationwide Population-Based Cohort Study. *Eur J Neurol* (2013) 20(10):1398–404. doi: 10.1111/ene.12197

Allen NE, Wong CM, Moloney N. The Association Between Parkinson’s Disease Motor Impairments and Pain. *Pain Med* (2016) 17(3):456–62. doi: 10.1111/pme.12898

Negre-Pages J, Regragui W, Bouchassar D, Grandjean H, Rascol O, DoPaMiP PSG. Chronic Pain in Parkinson’s Disease: The Cross-Sectional French DoPaMiP Survey. *Mov Disord* (2008) 23(10):1361–9. doi: 10.1002/mds.22142

Lee MA, Walker RW, Hildreth TJ, Prentice WM. A Survey of Pain in Parkinson’s Disease in Primary Care: A Case-Control Study. *Lancet Neurol* (2008) 7(5):425–9. doi: 10.1016/j.lneurol.2008.04.005

Mylius V, Engau I, Huemer R, Kommerell B, Schapka G, Drescher W, et al. Serum Immune Markers and Disease Progression in an Incident Parkinson’s Disease Cohort (ICICLE-Pd). *Mov Disord* (2016) 31(7):995–1003. doi: 10.1002/mds.26563

Bas J, Calopa M, Mestre M, Mollevi DG, Cutilias B, Ambrosio S, et al. Lympocyte Populations in Parkinson’s Disease and in Rat Models of Parkinsonism. *J Neuroimmunol* (2001) 113(1):146–52. doi: 10.1016/S0165-2478(00)00422-7

Calopa M, Bas J, Callen A, Mestre M. Apoptosis of Peripheral Blood CD4+ T Cells in Patients with Idiopathic Parkinson’s Disease: Evidence From a Case-Control Study. *Arch Neurol* (2008) 65(9):1191–4. doi: 10.1001/archneurol.2008.2

Blanchet PJ, Brefel-Courbon C. Chronic Pain and Pain Processing in Parkinson’s Disease. *Prog Neuropsychopharmacol Biol Psychiatry* (2018) 87(Pt B):200–6. doi: 10.1016/j.pnpbp.2017.10.010

Shestatsky P, Kumru H, Valls-Sole J, Valdeodores F, Marti MJ, Tolosa E, et al. Neurophysiologic Study of Central Pain in Patients With Parkinson Disease. *Neurology* (2007) 69(23):2162–9. doi: 10.1212/01.wnl.0000295669.12445.3d

Mylius V, Engau I, Trefzer P, Sturany-Koller K, Schepelmann K, Oertel WH, et al. Pain Sensitivity and Descending Inhibition of Pain in Parkinson’s Disease. *J Neurol Neurosurg Psychiatry* (2009) 80(1):24–8. doi: 10.1136/jnnp.2008.145995

Djadjeti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The Effect of Duloxetine on Primary Pain Syndromes in Parkinson’s Disease. *Clin Neuropharmacol* (2007) 30(4):201–5. doi: 10.1097/WNF.0b013e3180340319

Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of Levodopa on Pain Threshold in Parkinson’s Disease: A Clinical and Postural Emission Tomography Study. *Mov Disord* (2005) 20(12):1557–63. doi: 10.1002/mds.20629

Schrag A, Hordal L, Walters K, Noyce A, Petersen I. Prognostic Predictions of Parkinson’s Disease in Primary Care: A Case-Control Study. *Lancet Neurol* (2015) 14(1):57–64. doi: 10.1016/S1474-4422(14)70287-X

Waser G, Desuchi G. Pains in Parkinson Disease–Many Syndromes Under One Umbrella. *Nat Rev Neurol* (2012) 8(5):284–94. doi: 10.1038/nrneurol.2012.54

Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al. Peripheral Cytokines Profile in Parkinson’s Disease. *Brain Behav Immun* (2009) 23(1):55–63. doi: 10.1016/j.bbi.2008.07.003

Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P, Interience-1 Beta and Interence-6 are Elevated in the Cerebrospinal Fluid of Alzheimer’s and De Novo Parkinson’s Disease Patients. *Neurosci Lett* (1995) 202(1-2):17–20. doi: 10.1016/0304-3990(95)12192-7

Grozdanov V, Bliederhauser C, Ruf WP, Roth V, Fundel-Clemens K, Zonder L, et al. Inflammatory Disregulation of Blood Monocytes in Parkinson’s Disease Patients. *Acta Neurobiol* (2014) 75(5):651–63. doi: 10.1007/s00401-014-1345-4

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Naragut S. Interleukin (IL)-1 Beta, IL-2, IL-4, IL-6 and Transforming Growth Factor-Alpha Levels are Elevated in Ventricular Cerebrospinal Fluid in Juvenile Parkinsonism and Parkinson’s Disease. *Neurosci Lett* (1996) 211(1):13–6. doi: 10.1016/0304-3940(96)12706-3

Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Abrasions in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-Analysis. *JAMA Neurol* (2016) 73(11):1316–24. doi: 10.1001/jamaneurol.2016.2742

Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans J, et al. Serum Immune Markers and Disease Progression in an Incident Parkinson’s Disease Cohort (ICICLE-Pd). *Mov Disord* (2016) 31(7):995–1003. doi: 10.1002/mds.26563

Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson’s Disease: Prevalence and Characteristics. *Pain* (2009) 141(1-2):173–7. doi: 10.1016/j.pain.2008.12.004

Skogar O, Fall PA, Hallgren G, Bringer B, Carlsson M, Lennartsson U, et al. Parkinson’s Disease Patients’ Subjective Descriptions of Characteristics of Chronic Pain, Sleep Patterns and Health-Related Quality of Life. *Neuropsychiatr Dis Treat* (2012) 8:435–42. doi: 10.2147/NDT.S34882

Ha AD, Jankovic J. Pain in Parkinson’s Disease. *Mov Disord* (2012) 27(4):485–91. doi: 10.1002/mds.23959

Zis P, Grunewald RA, Chaudhari RK, Hadjivassiliou M. Peripheral Neuropathy in Idiopathic Parkinson’s Disease: A Systematic Review. *J Neurol Sci* (2017) 378:204–9. doi: 10.1016/j.jns.2017.05.023

Roversi et al. Parkinson’s Induced Pain

Roversi et al. Parkinson's Induced Pain

107. Nolano M, Proverita V, Manganelli F, Iodice R, Stancanelli A, Caporaso G, et al. Loss of Cutaneous Large and Small Fibers in Naïve and L-Dopa-Treated PD Patients. Neurology (2017) 89(8):776–84. doi: 10.1212/wnl.0000000000004274

108. Wang N, Gibbons CH, Lafa J, Freeman R. Alpha-Synuclein in Cutaneous Autonomic Nerves. Neurology (2013) 81(18):1604–10. doi: 10.1212/ WNL.0b013e3182e9f41a

109. Rodriguez-Leyva I, Calderon-Garcidueñas AL, Jimenez-Capdeville ME, Renteria-Palomino AA, Hernandez-Rodriguez HG, Valdes-Rodriguez R, et al. Alpha-Synuclein Inclusions in the Skin of Parkinson’s Disease and Parkinsonism. Ann Clin Transl Neurol (2014) (7):471–8. doi: 10.1002/acn3.78

110. Chen Y, Mao CJ, Li SJ, Wang F, Chen J, Zhang HJ, et al. Quantitative and Fiber-Selective Evaluation of Pain and Sensory Dysfunction in Patients With Parkinson’s Disease. Parkinism Relat Disord (2015) 21(4):361–5. doi: 10.1016/j.parkreldis.2015.01.008

111. Lodygin D, Herrmann M, Schweinigruber N, Fliegel-Koch C, Watanabe T, Schlosser C, et al. Beta-Synuclein-Reactive T Cells Induce Autoimmune CNS Grey Matter Degeneration. Nature (2019) 566(7745):503–8. doi: 10.1038/s41586-019-0964-2

112. Ferreira N, Goncalves NP, Jan A, Jensen NM, van der Laan A, Molseni S, et al. Trans-Synaptic Spreading of Alpha-Synuclein Pathology Through Sensory Afferents Leads to Sensory Nerve Degeneration and Neuropathic Pain. Acta Neuropathol Commun (2021) 9(1):31. doi: 10.1186/s40478-021-01131-8

113. Ding H, Wang Q, Liu J, Qian W, Wang W, Wang J, et al. Alterations of Gene Expression of Sodium Channels in Dorsal Root Ganglion Neurons of Estrogen Receptor Knockout (ERKO) Mice Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP). Endocrine (2012) 42(1):118–24. doi: 10.1007/s12020-012-9637-8

114. Taguchi T, Katanosaka K, Yasui M, Hayashi K, Yamashita M, Watakusi K, et al. Peripheral and Spinal Mechanisms of Nociception in a Rat Reserpine-Induced Pain Model. Pain (2015) 156(3):415–27. doi: 10.1097/ 01.j.pain.0000460334.49255.5e

115. Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive Brain Activation in Patients With Neuropathic Pain Related to Parkinson’s Disease. Parkinism Relat Disord (2013) 19(5):548–52. doi: 10.1016/j.parkreldis.2013.02.003

116. Polli A, Weis L, Biundo R, Thacker M, Turolla A, Koutsikos K, et al. Anatomical and Functional Correlates of Persistent Pain in Parkinson’s Disease. Mov Disord (2016) 31(12):1854–64. doi: 10.1002/mds.26826

117. Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, et al. Pain in Parkinson’s Disease: Facts and Uncertainties. J Neurol (2013) 260(5):1332–8. doi: 10.1007/s00401-014-1343-6

118. Hawkes CH, Del Tredici K, Braak H. A Timeline for Parkinson’s Disease. Mov Disord (2013) 28(7):917–69. doi: 10.1002/mds.26077

119. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric Alpha-Synuclein Immunoreactive Inclusions in Meissner’s and Auerbach’s Plexuses in Cases Staged for Parkinson’s Disease-Related Brain Pathology. Neurosci Lett (2006) 396(1):67–72. doi: 10.1016/j.neulet.2005.11.012

120. Shannon KM, Keshavarzian A, Mutlu E, Dodia HB, Daian D, Jaglin JA, et al. Alpha-Synuclein in Colonic Submucosa in Early Untreated Parkinson’s Disease. Mov Disord (2012) 27(6):709–15. doi: 10.1002/mds.23838

121. Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, et al. Progression of Intestinal Permeability Changes and Alpha-Synuclein Expression in a Mouse Model of Parkinson’s Disease. Mov Disord (2014) 29(8):999–1009. doi: 10.1002/mds.25776

122. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric Alpha-Synuclein Pathology and Autonomic Degeneration in Parkinson’s Disease. Parkinsonism Relat Disord (2015) 21(4):789–94. doi: 10.1016/j.parkreldis.2015.01.008

123. Stankovic I, Petrovic I, Pekmezovic T, Markovic V, Stojkovic T, Dragansevic-Dragasevic I, et al. Vagotomy and Subsequent Risk of Parkinson’s Disease. J Neurol (2008) 255(7):917–69. doi: 10.1007/s00401-008-0193-x

124. Sung HY, Park JW, Kim JS. The Frequency and Severity of Gastrointestinal Symptoms in PD Patients With Early Parkinson’s Disease. J Mov Disord (2014) 7(1):1–12. doi: 10.14802/jmd.14002
144. Liu T, Gao Yj, Ji RR. Emerging Role of Toll-Like Receptors in the Control of Pain and Itch. *Neurosci Bull* (2012) 28(2):131–44. doi: 10.1007/s12264-012-1219-5

145. Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, et al. Meta-Analysis of Gut Dysbiosis in Parkinson’s Disease. *Mov Disord* (2020) 35(9):1626–35. doi: 10.1002/mds.28119

146. Lin CH, Chen CC, Chiang HL, Liu JM, Chang CM, Lu TP, et al. Altered Gut Microbiota and Inflamatory Cytokine Responses in Patients With Parkinson’s Disease. *J Neuroinflamm* (2019) 16(1):129. doi: 10.1186/s12974-019-1528-y

147. Zhu J, Paul WE. *CD4 T Cells: Fates, Functions, and Faults*. *Blood* (2008) 112(5):1557–69. doi: 10.1182/blood-2008-05-078154

148. Martin R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, et al. The Commensal Bacterium Faecalibacterium Prurnszii is Protective in Dnbs-Induced Chronic Moderate and Severe Colitis Models. *Inflamm Bowel Dis* (2014) 20(3):417–30. doi: 10.1097/MIB.0b013e3182762764

149. Sokol H, Pigneur B, Watterlot L, Lachhari O, Bermudez-Humenegn LG, Gratadoux JG, et al. Faecalibacterium Prurnszii is an Anti-Inflammatory Commensal Bacterium Identified by Gut Microbiota Analysis of Crohn Disease Patients. *Proc Natl Acad Sci U S A* (2008) 105(43):16731–6. doi: 10.1073/pnas.0804812105

150. Zhu C, Song K, Shen Z, Quan Y, Tan B, Luo W, et al. Roseburia Intestinalis Inhibits Interleukin17 Excretion and Promotes Regulatory T Cells Differentiation in Colitis. *Mol Med Rep* (2018) 17(6):7567–74. doi: 10.3892/mmr.2018.8833

151. Patterson AM, Mulder IE, Travis AJ, Lan A, Cerf-Bensussan N, Gaboriau-Routhiau V, et al. Human Gut Symbiont Roseburia Hominis Promotes and Regulates Innate Immunity. *Front Immunol* (2017) 8:1166. doi: 10.3389/fimmu.2017.01166

152. Shen Z, Zhu C, Quan Y, Yang J, Yuan W, Yang Z, et al. Insights Into Roseburia Intestinalis Which Alleviates Experimental Colitis Pathology by Inducing Anti-Inflammatory Responses. *J Gastroenterol Hepatol* (2018) 33(10):1751–60. doi: 10.1111/jgh.14144

153. Cloo-Garcia M, Andres-Marin N, Fernandez-Eulate G, Abecia L, Lavin JL, van Liempd S, et al. Gut Microbiome and Serum Metabonome Analyses Identify Molecular Biomarkers and Altered Glutamate Metabolism in Fibromyalgia. *EBioMedicine* (2019) 46:499–511. doi: 10.1016/j.ebiom.2019.07.031

154. Dekker Niter M, Mousa A, Barrett HL, Naderpoor N, de Courten B. Altered Gut Microbiota Composition Is Associated With Back Pain in Overweight and Obese Individuals. *Front Endocrinol* (Lausanne) (2020) 11:605. doi: 10.3389/fendo.2020.00605

155. Zhang J, Song L, Wang Y, Liu C, Zhang L, Zhu S, et al. Beneficial Effect of Butyrate-Producing Lachnospiraceae on Stress-Induced Visceral Hypersensitivity in Rats. *J Gastroenterol Hepatol* (2019) 34(8):1368–76. doi: 10.1111/jgh.14536

156. Bhattacharyya D, Mohite GM, Krishnamoorthy J, Gayen N, Mehra S, Navalkar A, et al. Lipopolysaccharide From Gut Microbiota Modulates Alpha-Synuclein Aggregation and Alters Its Biological Function. *ACS Chem Neurosci* (2019) 10(5):2292–36. doi: 10.1021/acschemneuro.8b00733

157. Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM. LPS Sensitizes TRPV1 via Activation of TLRI4 in Trigeminal Sensory Neurons. *J Dent Res* (2011) 90(6):759–66. doi: 10.1177/0022034511400225

158. Meseguer M, Alpizar YA, Lu C, Tajada S, Denlinger B, Fajardo O, et al. TRP Channels Mediate Acute Neurogenic Inflammation and Pain Produced by Bacterial Endotoxins. *Nat Commun* (2014) 5:3125. doi: 10.1038/ncomms4030

159. Boonen B, Alpizar YA, Sanchez A, Lopez-Quena A, Voets T, Talavera K, et al. Differential Effects of Fecal Microbiota Transplantation on Mptp-Induced Parkinson’s Disease Mice: Gut Microbiota, Glial Reaction and TLR4/TNF-Alpha Signaling Pathway. *Brain Behav Immun* (2018) 70:48–60. doi: 10.1016/j.bbi.2018.02.005

160. Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, et al. Fecal Microbiota Transplantation in Parkinson’s Disease Patients With Constipation: A Case Report. *Med (Baltimore)* (2019) 98(26):e16163. doi: 10.1177/MD.0000000000016163

161. Xue LJ, Yang XZ, Tong Q, Shen P, Ma SJ, Wu SN, et al. Fecal Microbiota Transplantation Therapy for Parkinson’s Disease: A Preliminary Study. *Med (Baltimore)* (2020) 99(35):e22035. doi: 10.1097/MD.0000000000022035

162. Erny D, Hrabe de Angelis AL, Jatlin D, Wieghofer P, Staszewski O, David E, et al. Host Microbiota Constantly Control Maturation and Function of Microglia in the CNS. *Nat Neurosci* (2015) 18(7):965–77. doi: 10.1038/nn.4030

163. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. *Science* (2013) 341(6145):569–73. doi: 10.1126/science.1241165

164. Arpaia N, Campbell C, Fan X, Diky S, van der Veeken J, de Roos P, et al. Metabolites Produced by Commensal Bacteria Promote Peripheral Regulatory T-Cell Generation. *Nature* (2013) 504(7480):451–5. doi: 10.1038/nature12726

165. Vinolio MA, Rodrigues HG, Nagbar RT, Curi R. Regulation of Inflammation by Short Chain Fatty Acids. *Nutrients* (2011) 3(10):858–76. doi: 10.3390/nu3100858

166. kukkar A, Singh N, Jaggi AS. Attenuation of Neuropathic Pain by Sodium Butyrate in an Experimental Model of Chronic Constriction Injury in Rats. *J Formos Med Soc* (2014) 113(12):921–8. doi: 10.1016/j.jfma.2013.05.013

167. Nohr MK, Egerod KL, Christiansen SH, Gille A, Offermanns S, Schwartz TW, et al. Expression of the Short Chain Fatty Acid Receptor Gpr41/Ffar3 in Autonomic and Somatic Sensory Ganglia. *Neuroscience* (2015) 290:126–37. doi: 10.1016/j.neuroscience.2015.03.040

168. Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective Effects of Fecal Microbiota Transplantation on Mptp-Induced Parkinson’s Disease. *Parkinson’s Induced Pain* (2021) 17:1744806921996520. doi: 10.1177/1744806921996520

169. Sampson TR, Delibes JW, Thron T, Janssen S, Shastrit GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. *Cell* (2016) 167(6):1469–80.e12. doi: 10.1016/j.cell.2016.11.018

Conflict of Interest: ST has an equity stake in Nocio Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.